Companies › S.Biomedics
2 active drug programs in 2 registered trials: 2 Phase 1; Neurology, Other; next expected readout Oct 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| PSA-NCAM(+) NPC (neural precursor cells derived from human embryonic stem cell l Neural precursor cell transplantation therapy | NCAM1 | Phase 1 | Spinal Cord Injury, Acute | Oct 2028 |
| Clusters of Autologous Dermal Fibroblasts (3D-F, FECS-DF) Autologous dermal fibroblast cell therapy for dermal regeneration and wrinkle reduction | – | Phase 1 | Crow's Feet | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04818203 | Clusters of Autologous Dermal Fibroblasts (3D-F, FECS-DF) | Phase 1 | Crow's Feet | Other | Jul 2025 |
| NCT04812431 | PSA-NCAM(+) NPC (neural precursor cells derived from human embryonic stem cell l | Phase 1 | Spinal Cord Injury, Acute | Neurology | Oct 2028 |
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.